Staphylococcal Infections - Pipeline Insight, 2024

This “Staphylococcal Infections - Pipeline Insight, 2024” report provides comprehensive insights about 22+ companies and 23+ pipeline drugs in Staphylococcal Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Staphylococcal Infections: Understanding

Staphylococcal Infections: Overview

Staphylococcus aureus is a significant human pathogen causing various invasive infections, such as bacteremia, infective endocarditis, and skin and soft tissue infections. Recent epidemiological shifts have highlighted an increase in healthcare-associated infections, notably infective endocarditis and device-related infections, alongside a rise in community-associated skin and soft tissue infections driven by virulent, antibiotic-resistant strains. With approximately 30% of the population colonized by S. aureus, understanding this bacterium's dual role as a commensal and pathogen is crucial. Staphylococcal infections are caused by bacteria from the Staphylococcus genus, with Staphylococcus aureus being the most pathogenic. These bacteria are commonly found on the skin and in the nose of healthy individuals, but can cause a variety of infections when they enter the body through a wound or cut. Staph infections can manifest as skin infections like boils and cellulitis, bloodstream infections that can lead to sepsis, bone and heart valve infections, food poisoning, pneumonia, and the life-threatening condition of toxic shock syndrome. The bacteria can spread from person to person or from contaminated objects, and certain factors like weakened immunity, chronic conditions, recent surgery, or use of medical devices can increase the risk of developing a staph infection.

Staphylococcal infections can manifest a wide range of symptoms depending on the type and location of the infection. Skin infections are the most common, and can present as painful, swollen, and red lesions, boils, or blisters that may contain pus. More serious invasive infections can affect the bones, causing pain, swelling, and fever, or the heart, leading to endocarditis with flu-like symptoms like fever, fatigue, and shortness of breath. Staphylococcal pneumonia may develop abscesses and empyema. Systemic infections like bacteremia and toxic shock syndrome can be life-threatening, with symptoms such as high fever, low blood pressure, and organ dysfunction.

The treatment and management of Staphylococcal Infections involve a multifaceted approach. Local measures like debridement and removal of catheters are essential, along with antibiotic therapy tailored to the severity of the infection and local resistance patterns. Drainage of abscesses, debridement of necrotic tissue, and removal of foreign bodies are crucial steps. Initial antibiotic selection depends on factors like the site of infection, illness severity, and the likelihood of resistant strains. Given the prevalence of methicillin-resistant strains, knowing local resistance patterns is vital for effective treatment. For serious infections, especially those in healthcare settings, initial empiric treatment should include antibiotics active against MRSA. Surgical care may be necessary for abscess drainage or removal of infected prosthetic devices. Consultation with infectious disease specialists is recommended for optimal adherence to treatment guidelines and improved patient outcomes.

"Staphylococcal Infections - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Staphylococcal Infections pipeline landscape is provided which includes the disease overview and Staphylococcal Infections treatment guidelines. The assessment part of the report embraces, in depth Staphylococcal Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Staphylococcal Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Staphylococcal Infections R&D. The therapies under development are focused on novel approaches to treat/improve Staphylococcal Infections.

Staphylococcal Infections Emerging Drugs Chapters

This segment of the Staphylococcal Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Staphylococcal Infections Emerging Drugs

Ceftobiprole: Basilea Pharmaceutica

Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive bacteria such as Staphylococcus aureus, including methicillin-resistant strains (MRSA), and Gram-negative bacteria. The drug is in the Registration stage of development for the treatment of patients with Staphylococcal Infections.

ALS-4: Aptorum

ALS-4 is a novel first-in-class orally administered small molecule drug based on an anti-virulence approach targeting staphylococcus aureus including MRSA. ALS-4 targets the antimicrobial resistant properties of the bacteria and is believed to render the bacteria highly susceptible to the host’s immune clearance. ALS-4 is targeted for potential administration on a standalone or on a combination basis with other existing antibiotics such as vancomycin. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Staphylococcal Infections.

HY-133: HYpharm GmbH

HYpharm GmbH and a consortium funded by the DZIF are cooperating in the area of production and preclinical development of the phage lysin protein HY-133. A joint early clinical development for the nasal decolonization of Staphylococcus aureus is specifically planned. The drug is currently in the preclinical stage of development for the treatment of Staphylococcal Infections.

Staphylococcal Infections: Therapeutic Assessment

This segment of the report provides insights about the different Staphylococcal Infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Staphylococcal Infections

There are approx. 22+ key companies which are developing the therapies for Staphylococcal Infections. The companies which have their Staphylococcal Infections drug candidates in the most advanced stage, i.e. Registration include, Basilea Pharmaceutica.

Phases

This report covers around 23+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Staphylococcal Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Staphylococcal Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Staphylococcal Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Staphylococcal Infections drugs.

Staphylococcal Infections Report Insights

• Staphylococcal Infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Staphylococcal Infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Staphylococcal Infections drugs?
• How many Staphylococcal Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Staphylococcal Infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Staphylococcal Infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Staphylococcal Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• HYpharm GmbH
• Aptorum
• Basilea Pharmaceutica
• Destiny Pharma
• Technophage
• Mabwell (Shanghai) Bioscience
• Armata Pharmaceuticals
• Trellis Bioscience
• Lytix Biopharma
• Locus Biosciences

Key Products

• HY-133
• ALS-4
• Ceftobiprole
• XF-73
• TP-102
• 9MW1411
• AP-SA02
• TRL1068
• LTX-109
• LBP-SA01

This product will be delivered within 1-3 business days.